Tipsheet
What matters at India’s listed companies
Earnings · Hospital & Healthcare · Small cap

Suraksha Diagnostic revenue lifts 21% as margins tighten

FY26 revenue climbs to ₹300.68 cr while profit growth stalls at 1.9%. The board initiates a ₹0.50 dividend.

5 earlier stories on Suraksha Diagnostic Ltd.
Mkt cap₹1,415 cr
P/E43.95×
ROE15.07%
Debt / eq.0.03
Div yld0.18%
20.7% Standalone revenue growth for the fiscal year ended March 31, 2026.

What's new

  • Standalone FY26 revenue reached ₹300.68 cr, up 20.7% over the prior year.
  • Profit after tax edged up 1.9% to ₹34.06 cr, signaling margin pressure.
  • The board approved a maiden dividend of ₹0.50 per share.

Why this matters

Top-line growth of 20.7% failed to reach the bottom line, with profit growth crawling at 1.9%. This reflects significant margin compression during the year. The dividend payout is a gesture of confidence, yet the underlying profitability trend requires closer scrutiny.

What we're watching

  • Whether margins rebound in the coming quarters.
  • Management commentary on the cost pressures affecting profitability.
  • The sustainability of the current dividend policy.

The full read

Suraksha Diagnostic booked standalone revenue of ₹300.68 crore for FY26, representing a 20.7% increase over the prior year. The gains at the top line, however, did not carry through to profitability. Profit after tax rose only 1.9% to ₹34.06 crore, which indicates clear margin compression as operating costs outpaced growth. The board attempted to offset the sentiment by recommending a dividend of ₹0.50 per share, a move that provides a 25% payout against no dividend in the previous year. Routine housekeeping matters, including auditor appointments, filled out the remainder of the disclosure. With no material surprises, these results settle into a familiar pattern for the diagnostic sector: high growth remains the objective, but managing the cost of that growth is the primary struggle.

Questions answered

What was the total profit for Suraksha Diagnostic in FY26?
The company reported a profit after tax of ₹34.06 crore for the year ended March 31, 2026.
Is the dividend a new development?
Yes, the board recommended a dividend of ₹0.50 per share, compared to nil in the previous year.
Mentioned: Suraksha Diagnostic Ltd.
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Suraksha Diagnostic Ltd.

Hospitals
₹1,413 cr
P/E 43.90×

Latest quarter · Mar 2026

Sales₹81 cr
Net profit₹6 cr
Op. margin+29.9%
EPS₹1.21

Strength & growth

Debt / equity0.03×
Current ratio1.10×
  1. 21 May 2026 · 7:21 PM IST Suraksha Diagnostic revenue lifts 21% as margins tighten
  2. 45d ago Suraksha Diagnostic transcript confirms previously issued FY27 guidance
  3. 50d ago Suraksha Diagnostic cools growth targets to 15% for FY27
  4. 51d ago Suraksha's revenue grew 22.5%, but profit fell 14% in Q4.
  5. 51d ago Suraksha Diagnostic's revenue grows 20%. Profit doesn't follow.